Background: Cardiovascular events (CVE) are a major cause of morbidity and mortality in end-stage renal disease (ESRD) patients. These patients are often excluded from CV clinical trials, and the prognostic factors associated with CVE in patients with ESRD have not been fully explored. We investigated the role of BNP and NT-proBNP in predicting the outcome and prognostic value in hemodialysis with ESRD patients. Methods: Baseline NT-proBNP and BNP, indices of dialysis adequacy, and biochemical characteristics were assessed in 217 dialysis patients with ESRD who were followed prospectively for 2 years or until death. CVE included cardiovascular death, myocardial infarction, heart failure and stroke. Results: Using multivariable Cox regression analysis, BNP and NT-proBNP remained predictive of cardiovascular mortality (BNP: hazard ratio 1.22, 95% confidence interval (CI) 1.21–11.04, p < 0.05; NT-proBNP hazard ratio 1.86, 95% CI 1.14–9.36, p < 0.05), fatal/nonfatal CHF (BNP: 1.35, 1.33–11.78, p < 0.05; NT-proBNP: 2.25, 1.54–12.68, p < 0.001) and fatal/nonfatal MI (BNP: 0.61, 2.38–19.53, p = 0.42; NT-proBNP: 1.90, 3.28–20.17, p < 0.001). NT-proBNP had better predictive value than BNP for mortality (area under the ROC curve (AUC) 0.83 vs. 0.61; p < 0.05). Conclusion: These data showed that BNP and NT-proBNP are very sensitive and specific predictors of CVE in dialysis patients.

Keywords:
End-stage renal disease, Cardiovascular events, Hemodialysis, BNP, NT-proBNP
1.
Foley RN: Cardiovascular disease and survival in ESRD. Saudi J Kidney Dis Transpl 1999;10:455–463.
2.
Foley RN, Parfrey PS: Cardiovascular disease and mortality in ESRD. J Nephrol 1998;11:239–245.
3.
Brunner FP, Selwood NH: Results of renal replacement therapy in Europe, 1980–1987. Registration Committee of the EDTA-ERA. Am J Kidney Dis 1990;15:384–396.
4.
Johnson DW, Craven AM, Isbel NM: Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. Hemodial Int 2007;11:1–14.
5.
Cheung BM, Kumana CR: Natriuretic peptides – relevance in cardiovascular disease. JAMA 1998;280:1983–1984.
6.
Stanton E, Hansen M, Wijeysundera HC, Kupchak P, Hall C, Rouleau JL: A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non-ischaemic origin. Eur J Heart Fail 2005;7:557–565.
7.
Inoue S, Murakami Y, Sano K, Katoh H, Shimada T: Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000;6:92–96.
8.
Mabuchi N, Tsutamoto T, Maeda K, Kinoshita M: Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure. Jpn Circ J 2000;64:765–771.
9.
Giannitsis E, Katus HA: Comparison of cardiac troponin T and troponin I assays – implications of analytical and biochemical differences on clinical performance. Clin Lab 2004;50:521–528.
10.
Lellouche N, Berthier R, Mekontso-Dessap A, Braconnier F, Monin JL, Duval AM, Dubois-Randé JL, Guéret P, Garot J: Usefulness of plasma B-type natriuretic peptide in predicting recurrence of atrial fibrillation one year after external cardioversion. Am J Cardiol 2005;95:1380–1382.
11.
Apple FS, Murakami MM, Pearce LA, Herzog CA: Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004;50:2279–2285.
12.
Gutierrez OM, Tamez H, Bhan I, Zazra J, Tonelli M, Wolf M, Januzzi JL, Chang Y, Thadhani R: N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements. Clin Chem 2008;54:1339–1348.
13.
Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS: Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2002;40:68–75.
14.
Khan IA, Fink J, Nass C, Chen H, Christenson R, deFilippi CR: N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol 2006;97:1530–1534.
15.
Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC Jr: Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006;47:345–353.
16.
Goetze JP, Jensen G, Møller S, Bendtsen F, Rehfeld JF, Henriksen JH: BNP and N-terminal proBNP are both extracted in the normal kidney. Eur J Clin Invest 2006;36:8–15.
17.
Haller C, Zehelein J, Remppis A, Müller-Bardorff M, Katus HA: Cardiac troponin T in patients with end-stage renal disease: absence of expression in truncal skeletal muscle. Clin Chem 1998;44:930–938.
18.
Wang AM, Lam CK, Yu CM, Wang M, Chan IS, Lui SF, Sanderson JE: Troponin T, left ventricular mass, and function are excellent predictors of cardiovascular congestion in peritoneal dialysis. Kidney Int 2006;70:444–452.
19.
DeLong ER, Delong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–845.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.